Morgan Stanley has carried out a detailed analysis of Fresenius SE shares. Here are the resulting results.
The US investment bank Morgan Stanley has lowered the price target for Fresenius from 34 to 33 euros and left the rating at “equal-weight”. After last year’s valuation-driven recovery, earnings performance (EPS) is likely to play a larger role in the relative winners and losers among Europe’s medical technology stocks in 2024, analyst Robert Davies wrote in an industry outlook on Monday. His favorite stocks are Smith & Nephew and Biomerieux, while he rates Straumann as the least attractive./gl/edh
Stock evaluation: The Fresenius SE share at the center of daily analyzes and evaluations
At 10:06 a.m., Fresenius SE shares fell. In XETRA trading, the paper slipped by 2.1 percent to EUR 28.39. The share certificate therefore still has an upside potential of 16.24 percent based on the specified price target. 109,391 Fresenius SE shares have been traded in trading so far. Since the beginning of 2024, Fresenius SE shares have climbed 1.1 percent. The Q4 2023 financial results are expected to be presented on February 21, 2024.
NEW YORK (dpa-AFX Analyzer) / editorial team finanzen.net
Publication of the original study: 08.01.2024 / 04:31 / GMT First distribution of the original study: date not specified in study / time not specified in study / time zone not specified in study
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 Para. 1 WpHG, Art. 20 Regulation (EU) 596/2014 for the analyst firm mentioned can be found at http://web.dpa-afx.de/offenstellenpflicht/ disclosure_duty.html.
Selected leverage products on Fresenius
With knock-outs, speculative investors can participate disproportionately in price movements. Simply select the lever you want and we will show you suitable open-end products on Fresenius
The leverage must be between 2 and 20
Advertising